studies

non squamous - mNSCLC - L1 - Wild Type (WT), pembrolizumab and pemetrexed plus platin vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-021, 2016 0.90 [0.42; 1.92] 0.90[0.42; 1.92]KEYNOTE-021, 201610%123NAnot evaluable deaths (OS) (extension)detailed resultsKEYNOTE-021, 2016 0.71 [0.45; 1.12] 0.71[0.45; 1.12]KEYNOTE-021, 201610%123NAnot evaluable PFS (extension)detailed resultsKEYNOTE-021, 2016 0.54 [0.35; 0.83] 0.54[0.35; 0.83]KEYNOTE-021, 201610%123NAnot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-021, 2016 0.53 [0.31; 0.91] 0.53[0.31; 0.91]KEYNOTE-021, 201610%123NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-021, 2016 3.06 [1.45; 6.45] 3.06[1.45; 6.45]KEYNOTE-021, 201610%123NAnot evaluable objective responses (ORR) (extension)detailed resultsKEYNOTE-021, 2016 2.80 [1.34; 5.83] 2.80[1.34; 5.83]KEYNOTE-021, 201610%123NAnot evaluable STRAE (any grade)detailed resultsKEYNOTE-021, 2016 3.47 [1.25; 9.62] 3.47[1.25; 9.62]KEYNOTE-021, 201610%121NAnot evaluable STRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 5.56 [1.49; 20.67] 5.56[1.49; 20.67]KEYNOTE-021, 201610%121NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-021, 2016 0.95 [0.29; 3.12] 0.95[0.29; 3.12]KEYNOTE-021, 201610%121NAnot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.04 [0.92; 4.52] 2.04[0.92; 4.52]KEYNOTE-021, 201610%121NAnot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-021, 2016 0.52 [0.05; 5.86] 0.52[0.05; 5.86]KEYNOTE-021, 201610%121NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-021, 2016 0.76 [0.25; 2.35] 0.76[0.25; 2.35]KEYNOTE-021, 201610%121NAnot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsKEYNOTE-021, 2016 4.44 [0.48; 40.91] 4.44[0.48; 40.91]KEYNOTE-021, 201610%121NAnot evaluable Acute kidney injury TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 4.32 [0.19; 97.73] 4.32[0.19; 97.73]KEYNOTE-021, 201610%121NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 0.79 [0.27; 2.29] 0.79[0.27; 2.29]KEYNOTE-021, 201610%121NAnot evaluable Blood creatinine increased TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 0.52 [0.02; 15.84] 0.52[0.02; 15.84]KEYNOTE-021, 201610%121NAnot evaluable Dizziness TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 4.32 [0.19; 97.73] 4.32[0.19; 97.73]KEYNOTE-021, 201610%121NAnot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.06; 17.21] 1.05[0.06; 17.21]KEYNOTE-021, 201610%121NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.06; 17.21] 1.05[0.06; 17.21]KEYNOTE-021, 201610%121NAnot evaluable Increased lacrimation (TRAE grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.14 [0.19; 24.25] 2.14[0.19; 24.25]KEYNOTE-021, 201610%121NAnot evaluable Pancytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 0.52 [0.02; 15.84] 0.52[0.02; 15.84]KEYNOTE-021, 201610%121NAnot evaluable Peripheral oedema TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Pneumonia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Sepsis TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.06; 17.21] 1.05[0.06; 17.21]KEYNOTE-021, 201610%121NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 0.52 [0.02; 15.84] 0.52[0.02; 15.84]KEYNOTE-021, 201610%121NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.14; 7.73] 1.05[0.14; 7.73]KEYNOTE-021, 201610%121NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable0.210.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:16 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 176 - treatments: 1081